All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
LONDON – Cytovation AS has raised $20 million in a series A, enabling it to expand the monotherapy arm of a phase I/II trial of its tumor membrane immunotherapy, Cypep-1, and to test it in three combination arms with the checkpoint inhibitor Keytruda (pembrolizumab).